Gyroscope Targeting ‘Huge’ Population With Dry AMD Gene Therapy
Executive Summary
Bringing gene therapy to the masses: company raises extra £50m in series B fundraising for novel dry macular degeneration treatment
You may also be interested in...
Syncona Biotechs Face Up To Trial Delays Over COVID-19
Clinical trials across the board are being impacted by coronavirus and Syncona, the investment powerhouse behind a number of UK cell and gene therapy biotechs, says that its portfolio companies are facing considerable delays.
Gyroscope Merger Creates Gene Therapy Biotech For Eye Disorders
A new UK/US biotech tie-up makes a company with the technology to deliver its gene therapies.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.